Trials / Withdrawn
WithdrawnNCT01501396
Megestrol Acetate With or Without Mirtazapine in Treating Cancer Patients With Weight Loss or Loss of Appetite
Treatment of Cancer Anorexia-cachexia Syndrome (CACS) With Mirtazapine and Megestrol Acetate
- Status
- Withdrawn
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Washington University School of Medicine · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This randomized phase II trial studies the safety and efficacy of megestrol acetate given with or without mirtazapine in treating cancer patients with weight loss and loss of appetite. To date, no pharmacologic interventions have been approved by FDA to treat cancer anorexia-cachexia syndrome (CACS). Megestrol acetate has been shown to increase appetite in cancer patients. Adding mirtazapine may provide a much more effective treatment and help improve quality of life.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Megestrol Acetate | |
| DRUG | Mirtazapine |
Timeline
- Start date
- 2013-09-01
- Primary completion
- 2015-09-01
- Completion
- 2015-09-01
- First posted
- 2011-12-29
- Last updated
- 2014-02-03
Source: ClinicalTrials.gov record NCT01501396. Inclusion in this directory is not an endorsement.